ArticleBioengineering & translational medicine2016
Stimuli-Responsive Delivery of Therapeutics for Diabetes Treatment.
Article in Bioengineering & translational medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- A Comprehensive Review on Engineering Release at the Molecular Level: Role of Functional Groups in Polysaccharide-Based Drug Delivery.Materials (Basel, Switzerland) · 2026Review
- Advanced biomimetic nanomedicines for cell-based therapeutics: prospects and challenges.Journal of biological engineering · 2026Review
- Smart nanomaterials enabling drug delivery and glucose monitoring for diabetes management.Discover nano · 2026Review
- Advancing Type 1 Diabetes Management: Integrating Novel Therapies, Technologies, and Adjunctive Approaches.Diabetes care · 2026Review
- Review
- Rational Fabrication of Copper Nanoclusters and In Vitro Study of Antioxidant Property.Nanomaterials (Basel, Switzerland) · 2025Article
- Advances in Nanomedicine for Precision Insulin Delivery.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Current Advances in Stimuli-Responsive Hydrogels as Smart Drug Delivery Carriers.Gels (Basel, Switzerland) · 2023Review
- Material design for oral insulin delivery.Med-X · 2023Review
- Glucose-responsive microneedle patch for closed-loop dual-hormone delivery in mice and pigs.Science advances · 2022Article
- Updates on Responsive Drug Delivery Based on Liposome Vehicles for Cancer Treatment.Pharmaceutics · 2022Review
- Novel Gels: An Emerging Approach for Delivering of Therapeutic Molecules and Recent Trends.Gels (Basel, Switzerland) · 2022Review
- Design and development of insulin microneedles for diabetes treatment.Drug delivery and translational research · 2022Review
- GLUT4-overexpressing engineered muscle constructs as a therapeutic platform to normalize glycemia in diabetic mice.Science advances · 2021Article
- Article
- Engineering biopharmaceutical formulations to improve diabetes management.Science translational medicine · 2021Review
- Developing Insulin Delivery Devices with Glucose Responsiveness.Trends in pharmacological sciences · 2021Review
- Recent Advances in Insulin Therapy.Diabetes technology & therapeutics · 2020Review
- Dual self-regulated delivery of insulin and glucagon by a hybrid patch.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Glucose-responsive insulin patch for the regulation of blood glucose in mice and minipigs.Nature biomedical engineering · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Diabetic therapeutics, including insulin and glucagon-like peptide 1 (GLP-1), are essential for diabetic patients to regulate blood glucose levels. However, conventional treatments that are based on subcutaneous injections are often associated with poor glucose control and a lack of patient compliance. In this review, we focus on the different stimuli-responsive systems to deliver therapeutics for diabetes treatment to improve patient comfort and prevent complications. Specifically, the pH-responsive systems for oral drug delivery are introduced first. Then, the closed-loop glucose-responsive systems are summarized based on different glucose-responsive moieties, including glucose oxidase (GOx), glucose binding protein (GBP), and phenylboronic acid (PBA). Finally, the on-demand delivery systems activated by external remote triggers are also discussed. We conclude by discussing advantages and limitations of current strategies, as well as future opportunities and challenges in this area.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.